Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02850146 · ClinicalTrials.gov registry record · Phase 1
18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study
A Phase 1 study of Cognition Disorders, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 7
- Study locations
NCT02850146: Completed Phase 1 study of Cognition Disorders, sponsored by University of Southern California.
NCT02850146 is a Phase 1 study of Cognition Disorders that has completed, run by University of Southern California. The registered enrollment target is 55 participants, below the 270-participant average among 9 other Cognition Disorders trials with a reported enrollment target (80% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02850146, a Phase 1 study of Cognition Disorders, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 7
- Study locations
Study Summary
Approximately 50 participants enrolled in the LEARN study (NCT02488720) will be enrolled in the LEARN-Tau study. The study designed to evaluate the imaging characteristics of 18F-AV-1451 in participants enrolled in the LEARN study and to expand the safety database of 18F-AV-1451. The study will run in parallel to the LEARN study. In this study, participants will undergo up to four (4) 18F-AV-1451 PET scans over a 4.5 year period. Imaging visits will occur at the throughout the participant's participation in the LEARN study (corresponding to LEARN Visit 1, between Visit 4 and 6, Visit 8, and Visit 11). The LEARN-Tau study will (1) look at change in the amount of tau protein in the brain over time, measured by the 18F-AV-1451 PET scan, (2) see if tau protein in the brain of older individuals is associated with memory problems and (3) evaluate the safety of 18F-AV-1451 and any side effects that might be associated with it. Site investigators, participants, and study partners will not be informed of the results of the 18F-AV-1451 PET scan results as they relate to the study; however, any findings that may be of potential medical concern will be provided for appropriate follow-up.
Conditions Studied
Interventions
- DRUG 18F-AV-1451
Study Locations (7)
Arizona
- Banner Alzheimer's Institute - Phoenix
Connecticut
- Yale University School of Medicine - New Haven
Florida
- Bioclinica Research North - The Villages
Massachusetts
- Brigham & Women's Hospital - Boston
New York
- University of Rochester Medical Center - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Rhode Island
- Butler Hospital Memory and Aging Program - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2016-08 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 1 |
What the finished NCT02850146 record still lists
NCT02850146 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 270-participant average among 9 other Cognition Disorders trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Cognition Disorders appearing as the primary indexed condition, and to 1 intervention - of which 18F-AV-1451 is the first listed.
NCT02850146 lists 7 locations in 7 states (Arizona, Connecticut, Florida).
Frequently Asked Questions
What is clinical trial NCT02850146 about?
NCT02850146 is a clinical study titled "18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study". Approximately 50 participants enrolled in the LEARN study (NCT02488720) will be enrolled in the LEARN-Tau study. The study designed to evaluate the imaging characteristics of 18F-AV-1451 in participants enrolled in the LEARN study and to expand the safety database of 18F-AV-1451. The study will run...
What is the current status of trial NCT02850146?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2016-08. Estimated completion is 2023-09-29.
What conditions does trial NCT02850146 study?
This clinical trial studies the following conditions: Cognition Disorders.
What interventions are being tested in trial NCT02850146?
The interventions under investigation include: 18F-AV-1451 (DRUG).
Who is sponsoring clinical trial NCT02850146?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02850146 being conducted?
This trial has 7 study locations across Arizona, Connecticut, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognition Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02850146's enrollment target sits among peer trials
55 8th of 9 higher than 2 of 9 other Cognition Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognition Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).
COMPLETED · Phase 1
-
The BRAIN Intensive Care Unit (ICU) Study: Bringing to Light the Risk Factors
ACTIVE NOT RECRUITING
-
PET Scan to Map the Areas of the Brain Involved in Planning
COMPLETED
-
Therapy for Depressed Elders With Thought Problems
COMPLETED · Phase 3
-
Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
COMPLETED
-
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia